$288 Million

Annexon Biosciences

Initial Public Offering

Bookrunner, July 2020

Annexon Biosciences, Inc. is a clinical-stage biopharmaceutical company targeting C1q, the initiating molecule of the classical complement pathway, to develop transformative therapies for autoimmune and neurodegenerative disorders of the body, eye and brain. The Company’s lead product candidate is ANX005, a monoclonal antibody that blocks the activation of the classical complement cascade at its initiation point by binding and blocking the function of C1q. ANX005 is initially being developed for the treatment of Guillain-Barré Syndrome, or GBS, a rare, acute, antibody-mediated autoimmune disease impacting the peripheral nervous system. The Company’s second product candidate, ANX007, is an antigen-binding fragment, or Fab, that is designed as an intravitreal agent for the treatment of ophthalmic neurodegenerative disorders.

More Like This

Sep 2020
$147 Million

Initial Public Offering

Lead Left Bookrunner

View Details
Sep 2020
$853 Million

Initial Public Offering

Passive Bookrunner

View Details
Aug 2020
$200 Million

Initial Public Offering

Bookrunner

View Details